Retrospective Analysis of Curatively Resected Biliary Tract Cancer
Research type
Research Study
Full title
International Retrospective Analysis of Curatively Resected Biliary Tract Cancer: Treatment Patterns and Clinical Outcomes
IRAS ID
346986
Contact name
John Bridgewater
Contact email
Sponsor organisation
AstraZeneca Canada
Duration of Study in the UK
0 years, 9 months, 29 days
Research summary
This study is a multi-country, multi-centre, non-interventional retrospective clinical chart review of patients with resectable Biliary Tract Cancer (BTC) at diagnosis, that subsequently have undergone a surgical resection with curative intent as part of routine clinical practice.
As this is a retrospective, non-interventional study, there are no study-specific interventional procedures required of the principal investigator (PI) or patient to meet the needs of the study objectives. Additionally, there are no protocol-mandated study visits, assessments, or procedures for patients in this study. Routinely collected patient data will be extracted from patient medical records for the purpose of this study.
The study aims to enrol 500 patients across the six countries included in the study (U.S., U.K., Italy, Spain, Thailand, and Japan). There will be 2 centres in the UK, enrolling approx. 100 patients between them.REC name
London - Queen Square Research Ethics Committee
REC reference
25/PR/0261
Date of REC Opinion
10 Apr 2025
REC opinion
Further Information Favourable Opinion